Session 3: TFR in CML
Chair: Dr David Ross

• Monitoring TFR - Challenges 
  (A/Prof Susan Branford)
• TFR in CML - Clinical Trial Update
  (Dr David Ross)
• Response definitions and endpoint determination 
  in CML clinical trials
  (Dr David Yeung)

Monitoring TFR - Challenges
A/Prof. Susan Branford, SA Pathology / Universities of Adelaide and South Australia

• The new frontier for CML is reaching a deep molecular response
• Clinical trial results over the next few yeares will establish the safe criteria for discontinuation of treatment
• Close molecular monitoring is required after TKI cessation to monitor for molecular response
• Appropriate molecular monitoring of TFR
• Important issues for monitoring patients who have ceased therapy

TFR in CML - Clinical Trial Update
Dr David Ross - SA Pathology / Universities of Adelaide and South Australia

• Overview of treatment-free remission studies
• TFR experience
• Second TFR
• Predictors for TFR
• Summary
  
  

CML - Beyond chronic phase
Dr David Yeung - SAHMRI / Royal Adelaide Hospital

• Survival analysis
• Endpoints and definitions
• Mutation assessment
• Molecular response assessment
• Early molecular response assessment - importance of study window